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Abstract: The Asian world is home to a multitude of venomous and dangerous snakes, which are
used to induce various medical effects in the preparation of traditional snake tinctures and alcoholics,
like the Japanese snake wine, named Habushu. The aim of this work was to perform the first
quantitative proteomic analysis of the Protobothrops flavoviridis pit viper venom. Accordingly, the
venom was analyzed by complimentary bottom-up and top-down mass spectrometry techniques.
The mass spectrometry-based snake venomics approach revealed that more than half of the venom
is composed of different phospholipases A2 (PLA2). The combination of this approach and an
intact mass profiling led to the identification of the three main Habu PLA2s. Furthermore, nearly
one-third of the total venom consists of snake venom metalloproteinases and disintegrins, and several
minor represented toxin families were detected: C-type lectin-like proteins (CTL), cysteine-rich
secretory proteins (CRISP), snake venom serine proteases (svSP), L-amino acid oxidases (LAAO),
phosphodiesterase (PDE) and 5′-nucleotidase. Finally, the venom of P. flavoviridis contains certain
bradykinin-potentiating peptides and related peptides, like the svMP inhibitors, pEKW, pEQW,
pEEW and pENW. In preliminary MTT cytotoxicity assays, the highest cancerous-cytotoxicity of
crude venom was measured against human neuroblastoma SH-SY5Y cells and shows disintegrin-like
effects in some fractions.
Keywords: snake venomics; viperidae; Protobothrops flavoviridis; Habu pit viper; bottom-up;
top-down; BPP; tripeptide metalloprotease inhibitor; cytotoxicity
1. Introduction
Since ancient times, people have been fascinated by snakes and ascribed to them a diverse set
of properties and character traits. Especially, in mythologies from South America through ancient
Egypt to the Asian world, snakes and snake-like creatures represent both good and evil [1–4]. Most of
them appear as symbols of wisdom and protection, and healing aspects have often been attributed to
them [2]. Even today, the Aesculapius, the snake-wrapped rod of the Hellenic god Asclepius, and the
winged Caduceus of Hermes symbolize medical, veterinarian and pharmacological professions [3].
On the other hand, based on encounters with humans, snakes are also known and feared for their bites
and their possible consequences. Most accidents with snakes were registered in the tropics and mainly
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involve contact with farmers during field work. In consequence, snake envenomation was restored, in
2017, to the list of neglected tropical diseases [5].
One of the perillous regions is Japan, home to more than 38 different venomous and non-venomous
snakes [6]. They coexist with man over the entire country, even on the smaller islands, wherein the
diverse climatic conditions play a decisive role in the distribution of snakes [7]. The more densely
inhabited areas exhibit a higher risk of bites and envenomation, which is further increased in the
subtropical regions during the warm summer months [7]. Representatives of the most dangerous snake
families in Japan are the Habu (Protobothrops flavoviridis; P. flavoviridis) and Mamushi (Gloydius blomhoffii)
pit vipers, as well as the colubrid, Yamakagashi (Rhabdophis tigrinus) and the oceanic Erabu Umi Hebi
(Laticauda semifasciata) [7–9].
Particularly in several Asian countries, but also in other countries, many snakes, mostly dangerous
ones, were used in special traditional medicines, e.g., in Japan, the P. flavoviridis, also known as
the Okinawa Habu, which gave the Habushu snake wine its name, because it contains a snake or
snake extract [10,11]. Commonly, these liquors contain high ethanol concentrations of ~40% and
are unproblematic to consume. However, in home-made liquors, lower ethanol concentrations are
also feasible, so that, in rare cases, drinking can cause intoxications as well as health impairment or
damage [12].
The Japanese Habu viper is a member of the venomous pit viper subfamily. In some cases,
P. flavoviridis is classified as another genus and named, Trimeresurus flavoviridis [13]. This snake is
endemic to 25 islands between Japan and Taiwan, whereas the largest areas of distribution are the
Amami (Kagoshima Prefecture) and the Okinawa Islands (Okinawa Prefecture). Morphological and
genetic differences in these populations are still being studied, in which a genetic gap between the two
island populations was shown [14,15]. The Habu is responsible for most envenomations on the Amami
Ohshima islands and nearby regions [16]. A bite, like that of one of the other vipers, could lead to less
dangerous, more local symptoms (pain, erythema, vomiting), or to more dramatic symptoms, such as
necrosis, acute kidney injury and death. At the beginning of the 20th century, the mortality rate was
10% [16,17]. The enhanced medical supply chains helped to decrease mortality to nearly 1% in 2013 [16].
One further main reason for the lower mortality rate is the development of potent antivenoms, which
were, until now, the only effective treatment for snake envenomation [18]. Since the start of antivenom
serotherapy trials against snake bites, more than 120 years have elapsed, but, until the present day,
snakebites are still a serious threat to humans, particularly those working in endemic areas [5,19]. The
composition of venoms defines the effect of an envenomation and is relevant for the development of
specific and effective antivenoms, but it also could provide components with physiological functions,
exploited for the development of drugs [20]. Hence, apart from the investigation of snake venoms for
providing therapies and cures for snake bites, the exploration of their drug potential represents an
important aspect of venom research.
As already mentioned above, venoms are a complex mixture of low molecular weight substances,
e.g., nucleotides, sugars and lipids, as well as different peptides and proteins, the latter of which
has enzymatic and non-enzymatic functions [18,21–23]. Habitat variation and the divergence of
prey, which exert an evolutionary pressure, are major aspects that could lead to changes in the
venom composition [14,24,25]. Even if the percentage composition differs from species to species,
and also between different separated populations of the same species, the main toxin families
in snakes have mostly been identified [18,26]. The toxins of vipers range from small natriuretic
peptides, bradykinin-potentiating peptides (BPPs), over cysteine-rich secretory proteins (CRISPs) and
phospholipases A2 (PLA2s) to high molecular serine- and metalloproteinases (svSPs, svMPs) [25,27].
The venom of P. flavoviridis has been under investigation for decades and is still a source of
new findings, e.g., in the case of C-type lectin-like proteins (CTL), which are known for their strong
effect on platelet aggregation [28–33]. Hence, two CTLs were firstly identified in the Habu snake
venom. One CTL binds the blood coagulation factors, IX and X (named IX/X-BP), whereas the
second has been described as an antagonist of the Willebrand factor receptor, GPIb, and is called,
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flavocetin-A [34,35]. Recent studies have shown that flavocetin-A, as a well-known protein, also
inhibits the collagen-binding α2β1 integrin, which is the main receptor of platelets and necessary for
platelet and cell activation [33,36].
Previous studies on the venom of P. flavoviridis were transcriptomic approaches and proteomic
studies, yet limited to a shot-gun analysis, which could not provide a detailed picture of the venom
composition [31,37]. Here, we report the first quantitative analysis of the P. flavoviridis venom, by a
combination of diverse mass spectrometric methods, to give a more accurate profile of the venom and
its composition. Therefore, a combined proteomic approach of bottom-up (BU) and top-down (TD)
mass spectrometry (MS), including intact mass profiling (IMP), was used for snake venomic analyses,
thus ensuring a high annotation coverage of the whole venom [38–40].
2. Results
2.1. Top-Down Analysis
In a first top-down (TD) analytical run, the venom of P. flavoviridis was analyzed by a venomic
workflow to quickly identify its native peptides and proteins. The application of the intact mass
profiling (IMP) revealed 80 different molecular masses (Figure 1, Table S1). Proteins could be detected
up to a size of ~31 kDa: 9 proteins in a range of 13–15 kDa and 6 in the range of 21–31 kDa. Dominant
mass signals of small peptides at m/z 430–617 were observed, at early gradient retention times,
in peaks 1–7. The small molecular determinants could be annotated manually and identified as
members of the bradykinin-potentiating peptides-related peptides (BPP-RP) (Figures S1–S9) [41,42].
The peaks 8–15 mainly exhibited masses of 7–8 kDa, putatively identified as disintegrins (DI) by IMP
and later confirmed by BU annotation. While the components with molecular masses of ~14 kDa,
including peaks 16, 17, 18 and 22, were identified as PLA2s, those with molecular masses of 21–28 kDa
were suspected as members of the svSP and CTL family (Table S1).
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were attributed to self-digestion, e.g., by metalloproteinases, an effect described previously in vitro 
for bothropasin and brevilysin H6 [43]. 
Figure 1. Total ion chromatogram of the P. flavoviridis venom for IMP and TD. The total ion counts in
P. flavoviridis crude venom were measured by the HPLC-ESI-MS of native crude venom. The relative
abundance was set to 100% for the highest peak. The peak nomenclature is based on the chromatogram
fractions (shown in Figure 2). The identified molecular masses of intact peptides and proteins are listed
Table S1.
Accordingly, the non-reduced venom of . flavoviridis revealed 9 diff rent proteins belonging to
five toxin families: PLA2, svMP, DI, BPP-RP and L-amino acid oxidases (LAAO) (Table S1). Interestingly,
most sequences were identified as fragments belonging to svMPs, which, however, were attributed to
self-digestion, e.g., by metalloproteinases, an effect described previously in vitro for bothropasin and
brevilysin H6 [43].
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Three different BPP-related peptides were annotated, containing a characteristic
pyro-glutamylated N-terminus (Table S1). Additionally, five protein masses were detected as
full-length proteins. For each of these, a disintegrin and the four PLA2s were annotated, with
different modifications (Table S1). Since these mass differences to the expected amino acid sequence
were indicated as parts of a longer fragment and did not have a distinct position, we assume the
identification of closely related isoforms.
In order to further increase the number of annotations and assignments achieved so far, a
chemically reduced venom sample was measured (Figure S10). The reduction of cystines, which are
important post-translational modifications (PTMs) in snake venoms, breaks up the tertiary structures
and leads to a better fragmentation and de novo sequencing [39]. By means of the reduced TD
approach, we detected, among other fragments, proteoforms of two 14 kDa toxins. One CTL, with
a monoisotopic molecular mass of 14,400.38 Da, was identified as a 31.11 Da lighter variant of the
so-called IX/X-BP CTL. The second mass (13,921.36 Da) belongs to the PLA2 family and was annotated
as a proteoform of the basic phospholipase, A2 PL-X (13,971.41 Da). The reductive workup of venom
with tris(2-carboxyethyl)-phosphine (TCEP) ultimately leads to conformational changes in the proteins
and thus to differences in retention time. Therefore, a peak assignment, in comparison to the native
TD total ion chromatogram (TIC) nomenclature, was not possible.
Except for the BPP-RP, other isoforms of venom proteins were only detectable as fragments. It is
worth mentioning that, of the 73 TD assignments of the reduced venom, only three were annotated as
internal fragments, while 54 belong to the N-terminal end, and only 13 belong to the C-terminal end of
the compared sequences. The de novo sequences were assigned to seven toxin families (Table 1).
The high number of observed fragments could be an effect of the aforementioned digestion by
metalloproteinases, and thus an accurate peak annotation, in correlation with the native venom
TD, was impeded.
Table 1. Identified proteoforms and fragments of P. flavoviridis venom by reduced top-down analytics.
Assignment of reduced crude venom components by a top-down (TD) analysis. Sequence tags were
obtained de novo from MS/MS spectra and identified against a P. flavoviridis National Center for
Biotechnology Information (NCBI) protein database (taxid: 88087) by TopPIC.
Toxin Families Protein ID Highest E-Value NCBIAccession No.
No. of Sequence
Proteoforms
PLA2 basic phospholipase A2 BP-III 8.21 × 10−16 C7G1G6.1 20
basic phospholipase A2 PL-B 7.42 × 10−15 P59265.1 11
phospholipase A2 7.85 × 10−10 1202299A 11
basic phospholipase A2 PL-X 8.35 × 10−10 P06860.1 5
basic phospholipase A2 PLA-A 2.98 × 10−14 P59264.1 3
basic phospholipase A2 BP-II 3.70 × 10−6 P0DJJ9.1 2
basic phospholipase A2 BP-I 8.90 × 10−6 P0DJJ8.1 2
phospholipase A2 4.17 × 10−3 BAA01561.1 2
basic phospholipase A2 PL-Y 2.37 × 10−8 Q90Y77.1 1
svMP zinc metalloproteinase/disintegrin 1.29 × 10−6 P18619.2 3
P-II metalloprotease 5.12 × 10−5 BAN89360.1 1
snake venom metalloproteinase HR2a 2.16 × 10−3 P14530.3 1
snake venom metalloproteinase
trimerelysin-II 3.12 × 10
−3 P20165.3 1
DI disintegrin CTF-II 4.91 × 10−7 P23323.1 3
cytotoxic factor 9.96 × 10−8 AAB19943.1 1
disintegrin triflavin 4.67 × 10−4 P21859.1 1
LAAO L-amino acid oxidase 1.21 × 10−6 BAP39950.1 1
L-amino acid oxidase 1.28 × 10−4 BAN82013.1 1
CTL coagulation factor IX/X-binding protein 1.21 × 10−6 1IXX_F 1
BPP related Bradykinin-potentiating and C-typenatriuretic peptides 4.93 × 10
−6 BAP39952.1 1
CRISP CRISP Family Ca-Channel Blocker 7.52 × 10−5 1WVR_A 1
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2.2. Bottom-Up Analysis
The TD approach gave a first and quick overview of lower molecular mass peptides and proteins,
even of less prominent components, as constituents of the venom. A severe limitation of the TD
approach, however, is that proteins beyond a molecular mass of ~30 kDa are hardly detectable. This
requires complementary analytics by a bottom-up approach: HPLC fractionation (Figure 2A) of the
venom is followed by SDS-PAGE (Figure 2B) and a tryptic in-gel digestion of protein bands. The
subsequent MS de novo sequencing and semi-quantitative analysis led to the identification of the
following toxin families: 55.1% phospholipases A2 (PLA2), 31.3% snake venom metalloproteinases and
disintegrins (svMP/DI), 2.8% C-type lectin-like proteins (CTL), 1.8% cysteine-rich secretory proteins
(CRISP), 1.4% snake venom serine proteases (svSP), 0.7% L-amino acid oxidases (LAAO), 0.07%
phosphodiesterase (PDE) and 0.02% 5′-nucleotidase (5′-N). While 6.4% of the venom was assigned to
peptides, 0.3% could not be annotated (n/a) (Figure 3).
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Figure 2. HPLC P. flavoviridis venom profile and fractions, separated by SDS-PAGE. (A) Crude venom
from P. flavoviridis was separated on a Supelco Discovery BIO ide Pore C18-3 RP-HPLC column,
and components were detected at λ = 214 nm. Collected fractions (assigned above the correlated
peaks) were dried, and (B) separated by SDS-PAGE under reducing conditions (Coomassie staining).
Alphabetically marked bands per line were excised for a subsequent tryptic in-gel digestion.
According to the above findings, from components of the venom, the phospholipase A2 class
formed the biggest part and includes the three most abundant proteins in the whole venom: The
highest protein ntent belongs to the acidic PLA2 1 (16.6%), eluting as fraction 22. Secondly, the
basic PLA2 BP (10.4%) was identified in fraction 16 but could ot be cl arly assigned as PLA2 basic
protein I or II (BPI, BPII), beca se of their high similar y, which differs only in an N58D exchange as a
single mutation [44]. Th third protein is PLA-N(O) (7.9%) of fraction 17, which is PLA-N K121N
isoform (Uniprot-ID: S6BAM8), previously documented with respect to the P. flavoviridis population
on Okinawa Island [14].
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Figure 3. Semi-quantitative venom composition of P. flavoviridis. Relative occurrence of different
toxin families and peptide content in P. flavoviridis: Phospholipases A2 (PLA2, blue), snake venom
metalloproteinases and disintegrins (svMP/DI, red), C-type lectin-like proteins (CTL, violet), cysteine
rich secretory proteins (CRISP, light blue), snake venom serine proteases (svSP, light green), L-amino
acid oxidases (LAAO, dark green). Phosphodiesterases (PDE), 5′-nucleotidases (5′-N) and some
unidentified proteins (n/a) (combined in black and peptides in grey) are less abundant. Groups of
different peptide sizes are summarized in an additional pie chart percental related to the total peptide
content. They were clustered to <1 kDa (dull purple) and 1–3 kDa (dull brown) parts.
Th svMP and DI members were det cted at early retention tim s (HPLC fractions 4 and 5), but
also formed the dominating protein classes at later retention times (fractions 27, 28, 32) (Table S1).
Because svMP could include DI domains, both toxin families were combined in the final composition
as the svMP/DI part, thus forming the second most abundant group. The annotated sequences from
fractions 4–13 belong to svMP P-II disintegrin domains, but with ~15 kDa, the observed molecular
masses, determined from the SDS gel, appear too low for svMP P-II (expected molecular masses
30–60 kDa) and too high for single disintegrins (7–8 kDa). It is conceivable that the identified disintegrin
domains originate from degraded P-II or P-III metalloproteinases and contain neighboring sequence
parts. This could mean that the Habu venom contains truncated or auto-digested versions of svMP
P-II or P-III, which which is also known from other svMPs [43]. This autolysis was firstly observed for
the two svMPs, HR1A and HR1B, isolated from the P. flavoviridis venom [45,46].
The CRISPs represent a minor part of the venom (1.8%) and were only found in fractions 20 and
21. The BU-ann tated triflin revealed, in the IMP, a molecular mass of 24,767 Da, with a −16 Da shift
to the expected 24,783 Da. The transcriptomic data of P. flavoviridis i clude other CRISP (Uniprot-ID:
T2HP25), whose amino acid sequence diff rs from triflin (U iprot-ID: Q8JI39) in two mutations: D110N
and I113V. This isoform has an average molecular mass of 24,768 Da and would correspond to our
observation. To our knowledge, this proteoform, herein termed triflin-II, has not yet been described at
the proteomic level.
Another protein, validated by its molecular mass, is the flavoxobin (Uniprot-ID: P05620), which
belongs to the low abundant svSP family. This thrombin-like protease is the main part of fraction 25
and, with 0.8%, represents more than half of the svSP venom content, followed by svSP2 (Uniprot-ID:
O13057) with 0.3%. In summary, the combination of three mass spectrometric methods, BU, TD and
IMP, led to the annotation of specific isoforms (Table 2).
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Table 2. Identification of several venom isoforms by mass comparison. The bottom-up method (BU)
in combination with the intact mass profiling (IMP) leads to a database-oriented identification of
the isoforms in the crude venom. The theoretical mass includes oxidized cysteines for predicted
Cys-Cys bridges.
Fraction
Toxin
Family
Isoform Identity by UniProt-ID
for IMP
Average Mass in Da
BU IMP Observed Theoretical
16 PLA2 BPII
BPII P0DJJ9
13,752.4
13,752.1
BPI P0DJJ8 13,753.1
17 PLA2 PLA * PLA-N(O) S6BAM8 14,020.2 14,019.2
18 PLA2 PLA * PL-Y Q90Y77 13,944.3 13,945.2
20 CRISP triflin triflin-II T2HP25 24,767.2 24,767.9
22 PLA2 PLA2 1 PLA2 1 P06859 13,764.0 13,764.6
25 svSP flavoxobin flavoxobin P05620 25,686.4 25,687.4
* general identification as a member of the family.
In contrast to the proteomic data presented herein, the Habu is already known to have two
transcriptomic compositions from an mRNA analysis of the venom glands [31,37]. They exhibit small
analogies between the protein abundances and the fragments per kilobase million (FPKM %) of the
main toxin families, but also remarkable differences regarding the proportional distribution (Figure 4).
Both transcription analyses (T1, T2 in Figure 4) show PLA2 as the highest expressed gene family,
followed by svMP, which coincides with our proteomic data (P* in Figure 4). On the other hand, in T1,
the PLA2s form ~30%, while the amounts of P and T2 are comparable (~55%). With 17.3%, the svMP
gene expressions of T2 are lower than T1 and the protein amounts, identified in the proteome (~30%).
Interestingly, the proteomic and transcriptomic compositions are correlated in less represented groups:
CRISP (2–4%) and PDE (0.2–0.1%). In the other three families (CTL, svSP, LAAO), our measured
proteomic levels are much lower than the mRNA level. The data for CTL show an expression up to
five-fold and, for svSP, eight-fold, higher than that of the protein levels found. There is a considerable
difference between the observed 0.7% of LAAOs in our study and T1 as well as T2, which show a four
to 13-fold larger amount, accounting for up to 9.1% of the complete transcriptome. Due to the fact
that modern analysis can detect small amounts of RNA, very low concentrated targets can usually be
observed, but are not necessarily visible in proteomic approaches. All three studies identified PDEs
and 5′-nucleotidases, with abundances of >0.2%. In the case of T1 and T2, further families, in a range
of 0.65–0.01%, were observed, but not in the venomic proteome P: Galactose-binding lectins, nerve
growth factors, phospholipases B, glutaminyl cyclases, vascular endothelial growth factor-like proteins,
as well as less abundantly detected families, with <0.01% of the total transcript abundance [31,37]. This
underlines that reflecting the individual proteomic and transcriptomic compositions could not easily
be compared with independent venom analyses of a species. This has also been shown in studies
on other members of Viperidae and Elapidae [47–49]. However, these two approaches in combination
mutually represent a powerful aid for protein annotation and identification.
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Figure 4. Venomic data of P. flavoviridis in comparison to the closed related P. mucrosquamatus and
T. stejnegeri. Venom compositions of three proteomic pit viper analyses (P; quantified at 214 and 215 nm)
and two venom gland transcriptomic analyses of P. flavoviridis (T1 and T2) in fragments per kilobase
million (FPKM %). The asterisked data set P is the result of this study. “Other” represents, in all three
P. flavoviridis data, phosphodiesterases, 5′-nucleotidases and components that were not annotated.
Additionally, in the case of T1 and T2, galactose-binding lectins, nerve growth factors, phospholipases
B, glutaminyl cyclases, vascular endothelial growth factor-like proteins, as well as less abundantly
detected families, with <0.01%, are included. For P. mucrosquamatus (P3, P. mucro.), “other” represents
trimucrotoxin, and, for T. stejnegeri (P4, T. stejn.), “other” represents snake venom vascular endothelial
growth factors. The origins of toxin ratios are marked alphabetically: a [37], b [31], c and d [50]. The
phylogentic relationship is based on [15,51].
The venom of two related pit vipers show analogies in their composition to P. flavoviridis. This
concerns Protobothrops (or Trimeresurus) mucrosquamatus (P. mucrosquamatus), named the Taiwan Habu,
as well as the Trimeresurus stejnegeri (T. stejnegeri) (indicated with P3, P4 in Figure 4) [15,51]. As for
P. flavoviridis, they can be found on island habitats, e.g., Taiwan, in the south-west of Okinawa
at the end of the Japanese island chain, and the P. mucrosquamatus was also observed directly on
Okinawa [15,51,52]. Like the Habu from Japan, these two vipers belong to the medically important
venomous snakes in their Taiwanese habitat and are responsible for significant envenomations and
deaths over the last decades [53,54].
For all three snakes, the main venom families are svMPs and PLA2s, followed by CTLs, CRISPs,
svSPs, and LAAOs with abundances of <15%. While of the above-mentio ed P. flavoviridis venom (P* in
Figure 4) comprises a big portion, i.e., >55% PLA2s and >30% svMPs, the venoms of P3 and P4 are alike
to each otther. The main protein sha e of both venoms (P3 and P4 in Figu 4) is contributed by svMP,
with >40%, while the PLA2s (~25%) only constitute the second st abunda t protein compo ent and
thus stand in contrast to P*. The lesser protein families are twofold more abundant in P3 and P4, and
reflect a broader diversity of the venomous components in theses snakes. Particularly, the svSP with
>10% seemed to be more abundant in the P. mucrosquamatus and T. stejnegeri, than in the P. flavoviridis.
2.3. Bradykinin-Potentiating Peptides and Snake Venom Metalloproteinase Inhibitors
Besides the previously mentioned protein families, various bradykinin-potentiating peptides (BPP)
and snake venom metalloproteinases inhibitors (svMP-i) are further constituents of snake venoms.
The strong vasoactive effect of bradykinin, a substrate of the angiotensin-converting enzyme, was
discovered in the late 1940’s in studying the Bothrops jararaca venom, and this discovery indicates that
research on snake venoms can lead to impressive developments in the drug development field [55,56].
The identification of a small peptide in the same venom, which increased the effects of Kinin, was the
first BPP [57]. This facilitated the design of hypertension drugs based on the structure of a snake toxin
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structure [58]. Today, a multitude of different snake BPPs are known, and, with the progress in the
field of venomics, this number is still increasing.
By means of TD and IMP analytics, in total, we identified 5 different BPP-RP bearing an N-terminal
pyro-glutamate (pE): pEQWMPGGRPPHHIPP (Figure S1) and pESKPGRSPPISP (Figure S2). Until now,
the presence of both peptides was only hypothesized by transcriptomic data on P. flavoviridis [37,59].
In the peak of the BPP, pESKPGRSPPISP (peak 5, Figure S1), by means of MS/MS, two
C-terminally truncated versions were identified: The 11mer peptide, pESKPGRSPPIS (Figure S3),
and the 10mer, pESKPGRSPPI (Figure S4). Comparable to the peptide, pEQWMPGGRPPHHIPP, the
pEQWSQGRPR peptide (Figure S5) of peak 2 shows a trimeric N-terminal sequence (pEQW), which,
as a tripeptide, is known for its inhibition of svMP.
To minimize the risk of a self-degradation by metalloproteinases, also present in high
concentrations in the herein studied venom, snakes secrete small trimeric peptides. These svMP
inhibitors are processed from the same precursor, like the BPPs, and also contain an N-terminal
pyroglutamate [60]. In summary, we could identify three different svMP-is that represent the main
components of the TIC: Peak 4 (pEKW, m/z 444.22), peak 6 (pENW, m/z 430.17) and peak 7 (pEQW,
m/z 444.18) (Figures S6–S8). Another prominent molecular mass signal beneath the main peak, m/z
444.18, was detected at m/z 427.13 and could be identified as pEEW, which is the deaminated form
of peak 7 pEQW (Figure S9). Previously, these three svMP-is were further isolated from the closely
related Taiwanese Habu and revealed their strong inhibitory activity [61].
2.4. Cytotoxicity Test
It is well-known that the snake venom of P. flavoviridis causes strong cytotoxic effects and
various isolated toxins, e.g., LAAO Okinawa Habu apoxin protein-1 (OHAP-1) in glioma cells [62,63],
exhibiting in vivo apoptotic activities. The Habu venom was monitored in this study against several
human cancer cell lines and, therefore, the cytotoxicity was determined for cancerous (SH-SY5Y,
MDA-MB-231, A549, PANC1, HeLa, PC-3) as well as non-cancerous (HEK293) cells by the MTT assay.
The IC50 values range from ~1 to >50 µg/mL (Table 3).
Table 3. IC50 values of P. flavoviridis venom against human cell lines. The half maximal inhibitory
concentrations (IC50 in µg/mL) were determined for the crude venom of P. flavoviridis against one
non-cancerous (HEK-293) and six cancerous human cell lines. Error mean in ±SD.
Cell Line P. flavoviridis IC50 Values in µg/mL Doxorubicin IC50 Values in µg/mL
HEK-293 1.02 ± 0.02 0.002 ± 0.001
SH-SY5Y 4.68 ± 0.92 0.06 ± 0.02
MDA-MB-231 22.84 ± 2.51 4.98 ± 0.28
A549 38.51 ± 0.13 1.03 ± 0.37
PANC1 >50 0.05 ± 0.01
HeLa 24.78 ± 0.77 1.03 ± 0.25
PC-3 51.55 ± 2.79 2.02 ± 0.46
The highest inhibition of proliferation was found against HEK293 (1.02 µg/mL) and SH-SY5Y
(4.7 µg/mL) cells (Figure S11). SH-SY5Y, as the most sensitive cancer cell line, has been selected for
further screenings with single RP-HPLC venom fractions. Regarding the most abundant molecular
mass in a collected fraction, we indicated the IC50 in µg/mL and µM. While various tested fractions
were found to be active, fractions 4 and 7/8 were the most potent, with IC50 values of 0.7 and
0.9 µg/mL (Table 4). The main compound of the fraction 4 is the svMP-i pEKW, while the pEQW
containing fraction 7/8 is similarly potent. According to these results, the P. flavoviridis venom,
svMP-is, exhibits remarkable effects on SH-SY5Y cells, while, until now, only the correlating svMP
of most Protobothrops venoms were known to have an important role in envenomation-related
pathologies [46,64]. Regarding the identified families, PLA2s, as the main venom part, are most active
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in fraction 15 (PLA2, 2.2 µg/mL), in combination with a CTF-II-like disintegrin, against neuroblastoma
cells. An induced caspase-independent apoptosis by another PLA2 (BP-II) in a leukemia cell was
previously shown [63]. The PLA2 fractions (16, 17, 18, and 19) as well as the CRISP triflin-II fraction 20
revealed a moderate growth inhibition (16 to 30 µg/mL) with respect to the mass concentration.
Table 4. IC50 values of P. flavoviridis venom fractions against SH-SY5Y cells. Single RP-HPLC venom
fractions of P. flavoviridis were tested against human neuroblastoma SH-SY5Y cells, the half maximal
inhibitory concentrations (IC50) were determined in µg/mL, and the molar concentration in µM,
regarding the most abundant molecular mass, were determined in Da. Doxorubicin was used as a
reference and error mean in ±SD.
HPLC Fraction Molecular Mass in Da
IC50
in µg/mL in µM
4 443 0.680 ± 0.002 1.53 ± 0.01
5 1233 4.60 ± 0.24 3.73 ± 0.19
6 429 9.19 ± 1.22 21.42 ± 2.84
7/8 443 0.87 ± 0.05 1.96 ± 0.11
10 7508 49.63 ± 2.46 6.61 ± 0.33
11 7956 45.46 ± 7.45 5.71 ± 0.94
13 7956 17.94 ± 2.96 2.25 ± 0.37
14 7621 4.02 ± 0.24 0.53 ± 0.03
15 14,000 * 2.18 ± 0.12 0.16 ± 0.01
16 13,752 30.57 ± 1.50 2.22 ± 0.11
17 14,020 23.96 ± 2.55 1.71 ± 0.18
18 13,944 38.82 ± 2.82 2.78 ± 0.20
19 14,000 * 17.25 ± 0.98 1.23 ± 0.07
20 24,767 15.57 ± 1.10 0.63 ± 0.04
Doxorubicin 544 0.83 ± 0.20 1.53 ± 0.37
* based on SDS-PAGE size estimation.
Fractions 14 and 15 show an IC50 of 0.16 and 0.53 µM, respectively, and both are more active than
the positive control, doxorubicin (1.53 µM). Likewise, triflin-II (25 kDa), with an IC50 of 0.63 µM, is
highly potent. The effect on SH-SY5Y cells of the most active fractions, 14 and 15, as well as peptide
fractions, 4 and 7/8, is shown by microscopic imaging (Figure 5). Further tested fractions, with different
concentrations, are overviewed (Figure S12). Fractions 7/8 and 11–15 indicate, against SH-SY5Y cells
at higher concentrations, a disintegrine-like conglomeration effect (Figure S12), which correlates with
the observation of svMP/DI in these fractions by BU, IMP and the TD, like the disintegrin CTF-II
proteoform (Table S1). Future studies will focus on the mechanism of the P. flavoviridis venom action in
SH-SY5Y cells, notably due to DI and svMP-i.
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Figure 5. The most active P. flavoviridis venom fraction treatment of SH-SY5Y cells. Single RP-HPLC
venom fractions of P. flavoviridis, with the aforementioned mass concentration in µg/mL and molar
concentration in µM, were tested against human neuroblastoma SH-SY5Y cells. Ima es were taken
after 48 h of reatme t at 37 ◦C. Doxorubicin was used as a positive cytotoxic control drug and no
stimulation as a negative control.
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3. Discussion
In this contribution, we report on the first quantitative mass spectrometry-guided proteomic
snake venom analysis of the pit viper, P. flavoviridis, one of the most feared and life-threatening snakes
in Japan. The combination of all three mass spectrometric methods (BU, TD and IMP) facilitates the
annotation of isoforms, respectively based on databases even without the full sequencing of every
protein. The combined data reveal that PLA2s (55.1%) comprise the major part of the venom, with PLA2
1, PLA2 BP I/II and PLA-N(O) as main representatives, as well as the svMP/DI group and several
minor represented toxin families, like the svSP with flavoxobin and svSP2. For the first time, a CRISP
triflin-homolog, named triflin-II, was observed at the proteomics level. The top-down approach to
identify proteins as well as peptides was reliable for toxins with molecular masses up to ~30 kDa.
Venom compounds, in a range of m/z 338.1 to 30,384.7, were detected by the intact mass profiling,
with the same restrictions for high masses as in the top-down approach, while the SDS-PAGE exhibits
proteins over 100 kDa.
An analytical correlation of the proteomes, with two further pit viper venoms, shows that a close
relationship and similar habitats are not predictive of the venom compositions of related species. This
emphasizes the importance of an individual snake venom analysis to reveal the specific components,
e.g., those found for the various PLA2s of P. flavoviridis. Furthermore, these finding may help the
development of targeted snake bite therapies.
Interestingly, venom-peptides display various bioactivities, and their antiproliferative and
cytotoxic properties may also contribute to therapies in the treatment of cancer. This is corroborated
by the fact that several venom-based drugs are medically assessed, e.g., chlorotoxin, against different
tumor cell types and the integrin αvβ3-targeted cancer therapy [65–67]. In this study, we screened
fractions of the P. flavoviridis crude venom for cytotoxic effects against cancer cells. Accordingly,
cytotoxicity assays of crude venom and growth inhibition by venom fractions revealed promising
results against SH-SY5Y neuroblastoma cells. The observed effect of svMP-i tripeptide, containing
fractions on cell growth inhibition, appears very interesting from a pharmacological viewpoint as
well as for a future mode of action studies, and it reveals a new facet of the bioactivity of these small
venom components. Moreover, we identified the three highly potent protein fractions, 14, 15 and 20,
with IC50 values, ranging between 0.16 and 0.63 µM, which are 2–10× fold lower than the cytostatic
doxorubicin. These aspects, concerning the bioactivity of components of the P. flavoviridis venom on
neuroblastoma cells, might be helpful in the development of future anti-cancer treatments.
Through the wide range quantification of the Okinawa habu venom, we could extend the picture
of the Japanese venomous snakes, of which only a few detailed analyses have addressed the whole
venomic level.
4. Materials and Methods
4.1. Sample Preparation and System Setup
The pooled Habu venom of six P. flavoviridis specimens (four females, two males) was purchased
from the Kentucky Reptile Zoo (Slayde, KY, USA) and kindly provided by Professor Dr. Johannes A.
Eble (University of Münster, Germany). The crude venom (with a final concentration of 10 mg/mL)
was dissolved in 10 µL HFo (1% (v/v) and centrifuged at 20,000× g for 5 min. Then, 30 µL of citrate
buffer (0.1 M, pH 4.3) was added. One half of the sample (20 µL) was chemically reduced by adding
10 µL of 0.5 M tris(2-carboxyethyl)-phosphine (TCEP) and incubated for 30 min at 65 ◦C, while
10 µL ultra-pure water was added to the other half, as a non-reduced/native sample. All samples
were centrifuged at 20,000× g for 5 min and submitted to IMP (native) and TD venomics (native,
reduced): HPLC-high-resolution (HR) ESI-MS/MS measurements were performed on a LTQ Orbitrap
XL mass spectrometer (Thermo, Bremen, Germany) coupled to an Agilent 1260 HPLC system (Agilent,
Waldbronn, Germany) using a Supelco Discovery 300 Å C18 (2 × 150 mm, 3 µm particle size) column.
The elution was performed by a gradient of ultra-pure water, with 0.1% formic acid (HFo) (v/v; buffer
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A), and acetonitrile (ACN), with 0.1% HFo (v/v; buffer B), at a flow rate of 1 mL/min. An isocratic
equilibration (5% B) for 5 min was followed by a linear gradient of 5–40% B for 95 min, 40–70% B for
20 min, 70% B for 10 min and a re-equilibration with 5% B for 10 min.
ESI settings were: 11 L/min sheath gas, 35 L/min auxiliary gas, spray voltage 4.8 kV, capillary
voltage 63 V, tube lens voltage 135 V, and capillary temperature 330 ◦C. The data-dependent acquisition
(DDA) mode was used for MS/MS experiments, with 1 µ scans and 1000 ms maximal fill time. The
precursor ions were selected, with a range of ±2 m/z and after two repeats within 10 s, excluded with
±3 m/z for a duration of 20 s. Three scan events were performed, with a normalized collision-induced
dissociation (CID) energy of 30% and 35%, and a higher-energy collisional dissociation (HCD) with
35% collision energy.
4.2. Intact Mass Profiling (IMP)
For IMP, the mass spectrometric data were inspected via the Xcalibur Qual Browser (Thermo
Xcalibur 2.2 SP1.48, Waltham, MA, USA), and the deconvolution of isotopically resolved spectra was
carried out using the XTRACT algorithm of Xcalibur Qual Browser. The protein assignment was
done by comparison with the retention times obtained from the HPLC runs. Sequence annotations
and molecular mass comparisons with protein database entries of P. flavoviridis (taxid: 88087) were
performed manually.
4.3. Top-Down (TD) Venomics
The top-down analytical data were obtained based on the protocol of Petras et al., 2016 [68],
with the following alterations: Data were inspected with the Qual Browser (Thermo Xcalibur 2.2
SP1.48) and prepared based on the TopPIC workflow. The .raw data were converted to a centroided
.mzXML using the MSconvert of the ProteoWizard package (http://proteowizard.sourceforge.net),
version 3.0.10577. The .mzXML data were deconvoluted to an .msalign file using MS-Deconv
(http://bix.ucsd.edu/projects/msdeconv), version 0.8.0.7370 (maximum charge 30, maximum mass
50,000, m/z tolerance 0.02, s/n ratio 1.0). The final sequence annotation was performed by TopPIC
(http://proteomics.informatics.iupui.edu/software/toppic/), version 1.0.0, with a targeted search
type, error tolerance of 15 ppm and an E-value cutoff at 0.01 by E-value computation.
Variable modifications were: Acetylation of Lys (+42.010565 Da), phosphorylation of
Ser, Thr and Tyr (+79.966331 Da), oxidation of Met (+15.994915 Da), N-terminal methylation
(+14.015650 Da), N-terminal pyro-Glu formation of Glu (−18.010565 Da) and Gln (17.026549 Da),
N-acetylhexoseamine formation of Arg (HexNAc +203.079373 Da) and, in the case of non-reduced
samples, a dehydrogenation of Cys (−1.007825 Da for each Cys), rendering Cys-Cys bridges.
A maximum of two unexpected modifications was allowed, with a 500 Da maximal mass.
The sequences were matched against a protein NCBI database of P. flavoviridis (taxid: 88087,
852 entries, 8 September 2017), manually validated and graphically visualized using the MS and
MS/MS spectra of the Xcalibur Qual Browser.
4.4. Bottom-Up (BU) Venomics
Lyophilized crude venom (4 mg) was dissolved, with a final concentration of 20 mg/mL,
in aqueous 3% (v/v) and ACN, with 1% (v/v) HFo. The solution was centrifuged at 20,000× g
for 5 min, and the supernatant was loaded onto a semi-preparative reversed-phase HPLC with a
Supelco Discovery BIO wide Pore C18-3 column (4.6 × 150 mm, 3 µm particle size) using an Agilent
1260 Low Pressure Gradient System (Agilent, Waldbronn, Germany). As a gradient buffer, ultra-pure
water, with 0.1% (v/v) HFo (buffer A), and ACN, with 0.1% (v/v) HFo (buffer B), were used, with a
flow rate of 1 mL/min. An isocratic equilibration (5% B) for 5 min was followed by toxin elution, with
a linear gradient of 5–40% B for 95 min, 40–70% B for 20 min and 70% B for 10 min.
Absorbance was measured at λ = 214 nm using a DAD detector, and 1 mL fractions were
automatically collected. Peaks of the chromatograms were manually pooled and vacuum dried
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(Thermo Speedvac, Bremen, Germany). Fractions were submitted to SDS-PAGE under reducing
conditions [69]. Coomassie (Blue G250, Serva, Heidelberg, Germany) stained protein bands were cut,
in-gel reduced with fresh dithiothreitol (100 mM DTT in 100 mM ammonium hydrogencarbonate,
pH 8.3, for 30 min at 56 ◦C) and alkylated with fresh iodoacetamide (55 mM IAC in 100 mM ammonium
hydrogencarbonate, pH 8.3, for 20 min at 25 ◦C). An in-gel trypsin (Thermo, Rockfeld, IL, USA)
digestion was performed (6.7 ng/µL in 10 mM ammonium hydrogencarbonate with 10% (v/v)
ACN, pH 8.3, for 18 h at 37 ◦C, with 0.27 µg/band). The peptides were extracted with 100 µL
aqueous 30% (v/v) ACN, with 5% (v/v) HFo, for 15 min at 37 ◦C, and the supernatants were
vacuum dried, re-dissolved in 20 µL aqueous 3% (v/v) ACN, with 1% (v/v) HFo, and submitted
to LC-MS/MS analysis.
The analytics of tryptic peptides were performed using a reversed-phase Grace Vydac 218MSC18
column (2.1 × 150 mm, 5 µm particle size) under the control of an Agilent 1260 HPLC system
(Agilent Technologies, Waldbronn, Germany). The HPLC separation operated with a flow rate of
0.3 mL/min. After an isocratic equilibration (5% B) for 1 min, the peptides were eluted, with a
linear gradient of 5–40% B for 10 min and 40–99% B for 3 min, washed with 99% B for 3 min and
re-equilibrated in 5% B for 3 min.
MS experiments were performed on an Orbitrap XL mass spectrometer (Thermo, Bremen,
Germany), with R = 15,000 at m/z 400 and at a maximum filling time of 200 ms for the first
product ion scans. MS/MS fragmentation of the most intense ion was performed in the LTQ using a
collision-induced dissociation (30 ms activation time); the collision energy was set to 30% and 35%.
The precursor ions were selected, with a range of ±2 m/z, and, after two repeats within 10 s, excluded
with ±3 m/z for a duration of 20 s.
LC-MS/MS data files (.raw) were converted into mgf files via MSConvert GUI of the ProteoWizard
package (http://proteowizard.sourceforge.net; version 3.0.10577) and annotated by DeNovo GUI
1.15.11 [70], with carbamidomethylated cysteine (+57.021464 Da) as a fixed modification. Variable
modifications were the acetylation of lysine (+42.010565 Da) and phosphorylation of serine and
threonine (+79.966331 Da).
The peptide sequences were matched against a non-redundant protein in the NCBI database of
P. flavoviridis (taxid: 88087) using BLASTP (http://blast.ncbi.nlm.nih.gov).
4.5. Relative Toxin Quantification
The percentage composition of the venom ingredients was calculated on the basis of a combination
of the RP-HPLC chromatogram and SDS-PAGE evaluation [71,72]. The peak integrals at UV214nm were
measured in comparison to the total sum of peak integrals. In the case of multiple component elution
in an HPLC fraction identified by SDS-PAGE staining, the integrated density ratio of the stained bands
was respectively used for the emphasis of peak integrals.
4.6. Data Accessibility
Mass spectrometry proteomics data (.mgf, .raw and output files) have been deposited at
the ProteomeXchange Consortium [73] (http://proteomecentral.proteomexchange.org) via the
MassIVE partner repository, under the project name “Venomics of the Okinawa Habu pit viper,
Protobothrops flavoviridis,” and the data set identifier, PXD009414.
4.7. Cell Culture and In Vitro Cytotoxicity Assay
Human cells were purchased from ATCC (Manassas, VA, USA) and cultivated in Dulbecco’s
modified Eagle’s medium, F-12 (DMEM/F-12, 10% fetal bovine serum (FBS), 2 mM/L glutamine,
100 U/mL penicillin, 100 mg/mL streptomycin) (Gibco, Carlsbad, CA, USA). The following cell
lines were used: HEK-293 (human embryonic kidney), SH-SY5Y (neuroblastoma), MDA-MB-231
(breast epithelial adenocarcinoma), A549 (human alveolar adenocarcinoma), PANC1 (pancreas
adenocarcinoma), HeLa (human cervix adenocarcinoma) and PC-3 (human prostate adenocarcinoma).
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In vitro cytotoxicity assays were performed with crude venom and HPLC fractions using a modified
3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazoliumbromide) (MTT). The protein concentrations
in saline were estimated using a BCA protein assay kit (Thermo-Scientific, Darmstadt, Germany) with
a 595 nm ultraviolet (UV)-visible spectrophotometer (VersaMax, Molecular Devices, San Jose, CA,
USA). Bovine serum albumin was used as a standard for the calibration line.
A modified MTT assay was used to determine the cytotoxicity of the snake venom. Therefore,
1 × 105 cells/mL were seeded in a 96-well microtiter plate. After 24 h of cultivation, the cells were
treated for 48 h at 37 ◦C with crude venom, with venom fractions or doxorubicin as positive cytotoxic
control drugs.
The optical density (OD) was measured in triplicates at λ = 570 nm (with a reference wavelength
of λ = 690 nm) by UV/Vis spectrophotometry (Thermo, Bremen, Germany). The cell viability was
determined with an absorbance of A:
Viable cells =
Atreated − Ablank
Auntreated − Ablank ·100 (1)
4.8. Morphological Studies
The morphological changes of the cells following treatment with crude venom or single RP-HPLC
venom fractions of P. flavoviridis were observed under an inverted microscope (Olympus, Toyo, Japan)
and compared to the control group following a 48 h treatment.
4.9. Half Maximal Inhibition of Growth (IC50) Determination
The half maximal inhibition of growth (IC50) was calculated based on a sigmoidal curve fitting
using a four-parameter logistic model, as compared to that of untreated controls, which was calculated
using Prism 5 software (GraphPad5, San Diego, CA, USA). Values are presented at a 95% confidence
interval and as the average of three independent measurements.
Supplementary Materials: The following are available online. Figures S1–S5: Annotated MS2 spectra of BPP-RP;
Figures S6–S9: Annotated MS2 spectra of tripeptidic svMP-I; Figure S10: P. flavoviridis-reduced venom, MS TIC, for
IMP and TD; Figure S11: P. flavoviridis venom, tested for cytotoxicity against different human cell lines; Figure S12:
SH-SY5Y cells after 48 h treatment with different P. flavoviridis venom fractions.
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